在SLE患者中 羟氯喹增加甲流疫苗免疫效力

2012-04-20 邵佩 陈颖娟 中国医学论坛报

  巴西一项研究显示,SLE患者接受免疫抑制治疗可降低甲型H1N1流感疫苗效力,但羟氯喹(CQ)可能会恢复患者的免疫原性。论文1月31日在线发表于《风湿病学》(Rheumatology)杂志。   该研究显示,与健康对照相比,泼尼松(PRED)、免疫抑制剂(IS)及PRED+IS治疗组SLE患者注射甲型H1N1流感疫苗后的血清转换率较低(P<0.0001),但CQ治疗组及未治疗组患者无显著差异。

  巴西一项研究显示,SLE患者接受免疫抑制治疗可降低甲型H1N1流感疫苗效力,但羟氯喹(CQ)可能会恢复患者的免疫原性。论文1月31日在线发表于《风湿病学》(Rheumatology)杂志。

  该研究显示,与健康对照相比,泼尼松(PRED)、免疫抑制剂(IS)及PRED+IS治疗组SLE患者注射甲型H1N1流感疫苗后的血清转换率较低(P<0.0001),但CQ治疗组及未治疗组患者无显著差异。若上述前3种治疗方案同时加用CQ,则各组患者血清转换率与未治疗组无显著差异。



    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1746441, encodeId=1fbd1e464410d, content=<a href='/topic/show?id=47fd164116e' target=_blank style='color:#2F92EE;'>#SLE患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16411, encryptionId=47fd164116e, topicName=SLE患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41535763769, createdName=wushaoling, createdTime=Tue Mar 26 03:11:00 CST 2013, time=2013-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798690, encodeId=4c591e98690f8, content=<a href='/topic/show?id=9e0569822f5' target=_blank style='color:#2F92EE;'>#甲流疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69822, encryptionId=9e0569822f5, topicName=甲流疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Nov 03 07:11:00 CST 2012, time=2012-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344867, encodeId=6663134486ec6, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Sun Apr 22 10:11:00 CST 2012, time=2012-04-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1746441, encodeId=1fbd1e464410d, content=<a href='/topic/show?id=47fd164116e' target=_blank style='color:#2F92EE;'>#SLE患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16411, encryptionId=47fd164116e, topicName=SLE患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41535763769, createdName=wushaoling, createdTime=Tue Mar 26 03:11:00 CST 2013, time=2013-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798690, encodeId=4c591e98690f8, content=<a href='/topic/show?id=9e0569822f5' target=_blank style='color:#2F92EE;'>#甲流疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69822, encryptionId=9e0569822f5, topicName=甲流疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Nov 03 07:11:00 CST 2012, time=2012-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344867, encodeId=6663134486ec6, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Sun Apr 22 10:11:00 CST 2012, time=2012-04-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1746441, encodeId=1fbd1e464410d, content=<a href='/topic/show?id=47fd164116e' target=_blank style='color:#2F92EE;'>#SLE患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16411, encryptionId=47fd164116e, topicName=SLE患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41535763769, createdName=wushaoling, createdTime=Tue Mar 26 03:11:00 CST 2013, time=2013-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798690, encodeId=4c591e98690f8, content=<a href='/topic/show?id=9e0569822f5' target=_blank style='color:#2F92EE;'>#甲流疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69822, encryptionId=9e0569822f5, topicName=甲流疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Nov 03 07:11:00 CST 2012, time=2012-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344867, encodeId=6663134486ec6, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Sun Apr 22 10:11:00 CST 2012, time=2012-04-22, status=1, ipAttribution=)]

相关资讯

回顾系统性红斑狼疮的十年研究进展

  2010年9月,《风湿病年鉴》[Ann Rheu Dis 2010,69(9):1603]刊发了希腊和美国学者的一篇联合综述文章,从病因、发病机制、病程和转归等数个方面对系统性红斑狼疮(SLE)在过去十年间的进展情况进行了全面回顾,非常有学习价值。          

孙凌云:系统性红斑狼疮(SLE)药物治疗研究进展

    南京大学医学院附属鼓楼医院孙凌云教授为本报记者介绍了本次会议中系统性红斑狼疮(SLE)相关内容。① 在病因学研究中,微小RNA-146A、干扰素(IFN)、长寿浆细胞等一些参与SLE发病的新分子、细胞等被发现并得到进一步研究;② SLE诊断进展主要见于神经精神狼疮领域,包括影像学评估和生物标志物的研究;③ 在治疗方面,狼疮肾炎(LN)诊疗的细节问题

病例讨论:SLE伴反复呕吐、腹胀、肾积水

来源:中国医学论坛报 作者:南京军区南京总医院 张炯 章海涛 刘志红   病历摘要   患者女,16岁,因“确诊系统性红斑狼疮(SLE)6个月,反复腹泻、呕吐4个月,加重3天”入院。患者因先后出现眼睑及下肢水肿、尿蛋白和尿隐血、多个关节疼痛、血常规三系减少等,于6个月前来我科就诊,并被诊为SLE。其中,SLE疾病活动性指数(SLE-DAI)为11分,肾活检示狼疮性肾炎Ⅳ型[活动性指数(AI)

PLoS ONE:左建平等青蒿素衍生物治疗系统性红斑狼疮研究再获进展

系统性红斑狼疮 (systemic lupus erythematosus, SLE)是自身免疫介导的、多系统累及的致死性自身免疫病。多年来,由于受病理机制复杂、治疗靶点缺乏、相关疾病动物模型周期过长等因素的制约,SLE治疗药物的研究进展缓慢。 中科院上海药物研究所左建平研究员课题组多年来致力于SLE治疗药物的研究,并取得了一定的研究成果。水溶性青蒿素衍生物SM934作为治疗SLE候选新药,